Navigation Links
GPhA Annual Meeting Focuses on Industry Opportunities and Challenges for 2008

BOCA RATON, Fla., Feb. 12 /PRNewswire/ -- More than 400 generic industry leaders, financial experts and political officials gathered today for the Generic Pharmaceutical Association (GPhA) Annual Meeting to discuss the critical issues facing the generic industry in 2008. With the theme of "Generics: The Right Choice for Better Health," conference participants discussed the industry opportunities and challenges in this important legislative and election year.

"Voters are going to the polls with access to affordable health care at the top of their minds," said GPhA President Kathleen Jaeger. "Generics -- and biogenerics -- are the solution to reducing health care costs while increasing access to quality care. With generics saving consumers and the federal government billions of dollars a year, it's clear that generics are the right choice for better health."

Today 65% of all U.S. prescriptions dispensed are filled with generics, at costs of 30% to 80% less than brands. This offers substantial savings for consumers, state governments and the health care system. In fact, a 1% increase in generic use saves consumers $4 billion annually.

On Capitol Hill and in state capitals across the country, the generic industry will be working to help consumers receive greater access to affordable medicines by:

-- Encouraging passage of federal legislation to create a safe and

workable Food and Drug Administration (FDA) approval pathway that

provides timely access to biogeneric medicines. Brand

biopharmaceutical medicines can cost hundreds of thousands of dollars

per patient, per year. Safe and effective generic versions of

biopharmaceutical medicines, or biogenerics, would save consumers

billions of dollars and provide countless patients with access to

lifesaving treatments.

-- Removing longstanding barriers to consumer access to generics


* Ensuring that FDA implements the citizen petition law passed by

Congress in 2007 to curb brand drug company efforts to delay generic


* Blocking the marketing of an authorized generic (the brand company's

own product repackaged and marketed either through a subsidiary or

third party) during the 180-day exclusivity period awarded to the

first generic competitor.

-- Providing sufficient supplemental Congressional funding for the FDA's

Office of Generic Drugs Increasing FDA-industry communications.

-- Addressing changes to the Medicaid pharmacy reimbursement rules to

ensure that they do not harm consumers' access to generics.

-- Approving free trade agreements, similar to the recent U.S.-Peru Free

Trade Agreement, that balance pharmaceutical innovation with access to

affordable generic medicines.

-- Enacting legislation to promote e-prescribing to increase patient


-- Stopping state "carve out" legislation that bars generic substitution

for various therapeutic classes of medicines. Carve outs cost states

millions of dollars.

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 65% of the total prescriptions dispensed in the United States, but only 20.5% of all dollars spent on prescription drugs.

SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
2. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
3. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
4. Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
7. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
8. Avicena Group to Present at 10th Annual BIO CEO & Investor Conference
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):